Inovio Biomedical Corp (NASDAQ:INO)

I can't really claim that Inovio is a bogus biotech. After all, they've gotten VGX-3100 to the threshold of phase III and achieved reasonably significant deals with Roche and MedImmune. Nevertheless, I think 670M is a generous valuation in a shaky market for biotech given the company's long history of operations without any approved products and constantly-changing focus. Most of their current pipeline is in early stage trials and it will be a long time before the VGX-3100 phase III trial generates a significant catalyst. Cash of 183M is respectable but he quarterly burn is in the teens. This might not be an intuitive short but could be used as a counterweight for beloved long positions that are showing stretchmarks amid this spring sector rebound.

Find what are the attributes the Immune system latches on in an antigen (any Antigen – be it virus, bacteria, mushroom or a cancer cell), encode antigen production instructions in a RNA plasmid. Introduce into the body and let the cells themselves manufacture the part of the antigen. Let the Immune system discover the antigen and mount an immune reaction and you have immuned the body to this said antigen.
Now, use that platform to make the body produce monoclonal antibodies it needs as medicine, and heal itself.
Now use the platform to make the body make hormones it needs for as long as you design it.
Add management that is heavily invested and know how to bring non dilutive financing and behold – magic!